| Old Articles: <Older 4851-4860 Newer> |
 |
The Motley Fool May 21, 2008 Brian Orelli |
OK, Last Vioxx Settlement, Honest! What's another $58 million when Merck's already forking over $4.85 billion?  |
Chemistry World May 19, 2008 Hepeng Jia |
China's one stop research shop John Oyler has founded a string of startups in the US, but in 2005 he chose China as his base to launch BioDuro, a life sciences Contract Research Organisation.  |
Information Today May 19, 2008 |
IGI Global Launches InfoSci-Medical Database The company is launching a new database covering innovations in biomedical informatics and healthcare technology.  |
The Motley Fool May 19, 2008 Brian Orelli |
What Will Icahn Do With Amylin? Carl Icahn recently took an initial position now worth around $200 million in Amylin Pharmaceuticals, and stockholders must be wondering about his motivation for the purchase.  |
Information Today May 15, 2008 |
ProQuest Hospital Collection Makes Its Debut The new ProQuest Hospital Collection has five health and medicine databases and includes full-text articles from 2,100 medical journals.  |
The Motley Fool May 15, 2008 Brian Orelli |
So-So Syneron A little growth is an acceptable outcome in the struggling medical laser industry.  |
The Motley Fool May 15, 2008 Brian Lawler |
You're Kidding Me, Cardiome! Canadian pharmaceutical company Cardiome is still awaiting an FDA decision on its lead drug.  |
The Motley Fool May 15, 2008 Brian Lawler |
What's Cooking at Flamel? The drugmaker makes finding partners to help pay for its hepatitis C and diabetes compounds a top priority.  |
The Motley Fool May 15, 2008 Brian Orelli |
Wanted: FDA Approval -- Pronto Teva and Amphastar have the courts on their side, but the FDA still stands in the way of a generic-drug launch.  |
Chemistry World May 14, 2008 Simon Hadlington |
Bird Flu's Drug Resistance Mapped UK scientists have shown exactly why a mutant version of the deadly bird flu virus H5N1 becomes resistant to the drug oseltamivir - marketed as Tamiflu.  |
| <Older 4851-4860 Newer> Return to current articles. |